# Biomarker-based Study in R/M SCCHN

> **NCT03088059** · PHASE2 · UNKNOWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 340 (estimated)

## Conditions studied

- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** Afatinib
- **DRUG:** Palbociclib
- **DRUG:** standard of care
- **DRUG:** IPH2201
- **DRUG:** Durvalumab
- **DRUG:** Niraparib
- **DRUG:** INCAGN01876

## Key facts

- **NCT ID:** NCT03088059
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-16
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2023-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088059, "Biomarker-based Study in R/M SCCHN". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03088059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*